Scleroderma as a paraneoplastic syndrome and tumors associated with scleroderma

Patients with systemic scleroderma, or systemic sclerosis (SS), have an increased risk of developing malignant neoplasms. Cancer can be diagnosed immediately prior to SS symptoms, at the stage of diagnosis and years after SS diagnosis. The first two cases may indicate scleroderma-like paraneoplastic syndrome. In this case, the main mechanism of paraneoplastic syndrome development is associated with immune system activation by antigens, expressed by tumor cells, which leads to the development of antibodies that cross-react with body tissues, causing damage and secondary regeneration. Thus, cancer induces autoimmunity – mutation-specific T-cell immune response, and pathogenetic mechanisms can be the same for fibrogenesis and oncogenesis.
SS clinical and laboratory characteristics that indicate paraneoplastic etiology include minimum time difference between diagnosing scleroderma and cancer, as well as oncopathology in a patient’s or family cancer history, late disease onset (after 50 years), SS symptoms in a man, sudden onset and rapid progression of clinical symptoms, expressed or atypical SS symptoms (malaise, fever, significant weight loss), asymmetric or absent Raynaud syndrome, antibodies against RNA polymerase III, absence of anticentromeric antibodies and anti-Scl70, deviations in laboratory tests indicating possible oncopathology (anemia, hypercalcemia, hypergammaglobulinemia), no response to SS treatment, disappearance of SS symptoms after anticancer treatment and their appearance when cancer reactivation. On the other hand, patients with scleroderma have an increased risk of all types of cancer, with men at higher risk than women. Continuous autoimmune stimulation, B-cell activation, chronic inflammatory process and fibrosis in SS patients can lead to malignant transformation in certain organ systems, especially in lungs.
The most important risk factor for lung cancer in SS patients is interstitial lung disease, requiring special attention from a physician. In addition to lung cancer, SS patients more likely than the general population suffer from malignant hematologic diseases, esophageal cancer, hepatocellular carcinoma and bladder cancer. Scleroderma-like skin changes are also possible when cytotoxic drugs are used to treat cancer (docetaxel, paclitaxel, bleomycin, etc.), as well as during radiation therapy.

systemic scleroderma, systemic sclerosis, malignancies, scleroderma-like paraneoplastic syndrome, borderline cancer, tumorassociated scleroderma, malignant transformation, circumscribed scleroderma, localized scleroderma, morphea, fibrogenesis, sclerodactyly, Raynaud syndrome, capillaroscopic changes of nailfold vessels, autoimmunity, antinuclear antibodies, autoantibodies to toisomerase I, anticentromeric antibodies, autoantibodies to RNA polymerase III, interstitial lung disease, Barrett’s esophagus, lung cancer, cytotoxicotherapy, cyclophosphamide, docetaxel, bleomycin, cancer prevention

1. Tyndall A.J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma. Trials and research (EUSTAR) database. Ann Rheum Dis 2010;69(10):1809–15. DOI: 10.1136/ard.2009.114264.

2. Zhang J.Q., Wan Y.N., Peng W.J. et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol 2013;37(5):523–7. DOI: 10.1016/j.canep.2013.04.014.

3. Shah A.A., Rosen A. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 2011;23(6):530–5. DOI: 10.1097/BOR.0b013e32834a5081.

4. Kowal-Bielecka O., Bielecki M. Twardzina układowa. W: Reumatologia. Wielka interna. Ed. M. Puszczewicz, Warszawa: Medical Tribune Polska, 2010. Ss.: 127–41. [Kowal-Bielecka O., Bielecki M. Systemic sclerosis. In: Rheumatology. Great Internet. Ed. M. Puszczewicz, Warsaw: Medical Tribune Polska, 2010. Pp.: 127–41.(In Polish).

5. Joseph C.G., Darrah E., Shah A.A. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014;343(6167):152–7. DOI: 10.1126/science.1246886.

6. Pelosof L.C., Gerber D.E. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 2010;85(9):838–54. DOI: 10.4065/mcp.2010.0099.

7. Schmalzing M. Paraneoplastic syndromes in rheumatology. Z Rheumatol 2018;77(4):309–21. DOI: 10.1007/s00393-018-0445-2.

8. Hachulla E., Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011;40(2):78–83. DOI: 10.1007/s12016-010-8198-y.

9. Keragala B.S.D.P., Herath H.M.M.T.B., Janappriya G.H.D.C. et al. Scleredema associated with immunoglobulin A-κ smoldering myeloma: a case report and review of the literature. J Med Case Rep 2019;13(1):145. DOI: 10.1186/s13256-019-2072-1.

10. Marek M., Rudny R. Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome – description of two cases. Reumatologia 2016;54(2):91–4. DOI: 10.5114/reum.2016.60220.

11. Lambova S., Müller-Ladner U. Capillaroscopic pattern in paraneoplastic Raynaud’s phenomenon. Rheumatol Int 2013;33(6):1597–9. DOI: 10.1007/s00296-010-1715-8.

12. Shah A.A., Casciola-Rosen L. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol 2015;27(6):563–70. DOI: 10.1097/BOR.0000000000000222.

13. Airo’ P., Ceribelli A., Cavazzana I. et al. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011;38(7):1329–34. DOI: 10.3899/jrheum.101144.

14. Catano J., Guedon A., Riviere S. et al. Cancers in systemic sclerosis: risk factors, impact on survival and literature review. Rev Med Interne 2019;40(10):637–44. DOI: 10.1016/j.revmed.2019.06.004.

15. Onishi A., Sugiyama D., Kumagai S., Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013;65(7):1913–21. DOI: 10.1002/art.37969.

16. Kang K.Y., Yim H.W., Kim I.J. et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 2009;38(4):299–303. DOI: 10.1080/03009740802642062.

17. Colaci M., Giuggioli D., Sebastiani M. et al. Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev 2013;12(3):374–9. DOI: 10.1016/j.autrev.2012.06.003.

18. Derk C.T., Rasheed M., Artlett C.M., Jimenez S.A. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33(6):1113–6.

19. Wipff J., Coriat R., Masciocchi M. et al. Outcomes of Barrett’s oesophagus related to systemic sclerosis: a 3-year EULAR scleroderma trials and research prospective follow-up study. Rheumatology (Oxford) 2011;50(8):1440–4. DOI: 10.1093/rheumatology/ker110.

20. Shah A.A., Xu G., Rosen A. et al. Brief Report: Anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma. Arthritis Rheumatol 2017;69(6):1306–12. DOI: 10.1002/art.40065.

21. Nadelman D.A., Orbuch D., Sandigursky S., Femia A.N. Systemic sclerosis with malignant acanthosis nigricans in a patient with gastric adenocarcinoma. JAAD Case Rep 2019;5(12):1045–7. DOI: 10.1016/j.jdcr.2019.10.003.

22. Marie I., Gehanno J.F., Bubenheim M. et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014;13(2):151–6. DOI: 10.1016/j.autrev.2013.10.002.

23. Igusa T., Hummers L.K., Visvanathan K. et al. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 2018;77(8):1179–86. DOI: 10.1136/annrheumdis-2018-212999.

24. Zeineddine N., Khoury L.E., Mosak J. Systemic sclerosis and malignancy: a review of current data. J Clin Med Res 2016;8(9):625–32. DOI: 10.14740/jocmr2606w.

25. Rahmattulla C., Berden A.E., Wakker S.C. et al. Incidence of malignancies in patients with antineutrophil cytoplasmic antibodyassociated vasculitis diagnosed between 1991 and 2013. Arthritis Rheumatol 2015;67(12):3270–8. DOI: 10.1002/art.39317.

26. Okada K., Endo Y., Miyachi Y. et al. Glycosaminoglycan and versican deposits in taxane-induced sclerosis. Br J Dermatol 2015;173(4):1054–8. DOI: 10.1111/bjd.13899.

27. Hung C.H., Chan S.H., Chu P.M. et al. Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta: the protective effects of sotrastaurin. Toxicol Sci 2015;145(1):59–67. DOI: 10.1093/toxsci/kfv017.

28. Park B., Vemulapalli R.C. Gupta A. et al. Docetaxel-induced systemic sclerosis with internal organ involvement masquerading as congestive heart failure. Case Reports Immunol 2017;2017:4249157. DOI: 10.1155/2017/4249157.

29. Dvornikov A.S., Skripkina P.A., Dvornikov S.K. et al. Tumor-associated localized scleroderma in conjunction with acqired dissiminated form of vitiligo: a clinical case. Arkhiv” vnutrenney meditsiny = The Russian Archives of Internal Medicine 2017;7(1):60–5. (In Russ.) DOI: 10.20514/2226-6704-2017-7-1-60-65.

30. Shostak N.A., Dvornikov A.S., Klimenko A.A. Localized (focal) scleroderma in general medical practice. Lechebnoye delo = Medical business 2015;(4):45–52. (In Russ.)

31. Colver G.B., Rodger A., Mortimer P.S. et al. Post-irradiation morphoea. Br J Dermatol 1989;120(6):831–5. DOI: 10.1111/j.1365-2133.1989.tb01382.x.

32. Gonzalez-Ericsson P.I., Estrada M.V., Al-Rohil R., Sanders M.E. Post-irradiation morphoea of the breast: a case report and review of the literature. Histopathology 2018;72(2):342–50. DOI: 10.1111/his.13343.

33. García-Arpa M., Lozano-Martín E., Rodríguez C.R., Rodríguez-Vázquez M. Morphea following radiation therapy in a patient with breast cancer. Actas Dermosifiliogr 2015;106(3):243–5. DOI: 10.1016/j.ad.2014.07.005.

34. Mittal A., Mittal V., Panse G. еt al. Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy. J Am Acad Dermatol 2019;81(1):260–2. DOI: 10.1016/j.jaad.2019.02.039.

35. Machan A., Oumakhir S., Khalidi M. et al. Radiation-induced morphea: autoimmunity as a risk factor. Neth J Med 2019;77(1):29–31. PMID: 30774102.

36. Kim S.R., Charos A., Damsky W. et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep 2018;4(5):443–5. DOI: 10.1016/j.jdcr.2017.12.003.

37. Starodubov V.I., Dvornikov A.S., Shevchenko A.G., Lopakov K.V. Estimation of the prospects for early detection of diseases in russia on the base of questionnaire of users of internet about their attitudes toward prophylaxis. Sotsial’nyye aspekty zdorov’ya naseleniya = Social Aspects of Population Health 2011;3(19):2. (In Russ.)